Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.45 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3749345 | 0.88 | HSPA1A (0.51) | HSPA1APTPN7SIRT1ALDH1A1KDM4E | |
| SCHEMBL22864660 | 0.87 | MAPK1 (0.39) | MAPKAPK2MTNR1A | |
| SCHEMBL19644392 | 0.85 | SIRT1 (0.43) | HSPA1APTPN7SIRT1ALDH1A1KDM4E | |
| SCHEMBL7946579 | 0.84 | HDAC8 (0.38) | ALDH1A1KDM4EMTNR1AHTR2C | |
| SCHEMBL28981598 | 0.84 | MTNR1A (0.36) | HSPA1APTPN7ALDH1A1KDM4EMTNR1A | |
| SCHEMBL3903010 | 0.76 | PRKAB2 (0.44) | ALDH1A1MAPKAPK2 | |
| SCHEMBL3906901 | 0.76 | PRKAB2 (0.39) | ALDH1A1KDM4EHPGDHSD17B10MAPKAPK2 | |
| SCHEMBL5809094 | 0.76 | PRKAB2 (0.39) | ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL14885415 | 0.76 | PRKAB2 (0.42) | HSPA1APTPN7ALDH1A1 | |
| SCHEMBL12649161 | 0.76 | HTR2C (0.54) | MAPKAPK2MTNR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624321-B2 | Metathesis ring-opening polymerization of cyclic ethers in the presence of catalysts such as aluminum bis(trifluoromethane-sulfonate) phenolate | BAYER AKTIENGESELLSCHAFT (DE) | 2003-09-23 | — | — | US | disclosed |
| US-20030097026-A1 | Process for the preparation of polyether polyols | DENNINGER UWE (DE) | 2003-05-22 | — | — | US | disclosed |
| US-6492565-B2 | USING ALKYLENE OXIDE IN PRESENCE OF LEWIS ACID CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-10 | — | — | US | disclosed |
| US-20010053866-A1 | Process for the preparation of polyether polyols | BAYER AKTIENGESELLSCHAFT (DE) | 2001-12-20 | — | — | US | disclosed |
| EP-1032570-A1 | ISOQUINOLINE DERIVATIVES AND THEIR THERAPEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999025709-A1 | ISOQUINOLINE DERIVATIVES AND THEIR THERAPEUTICAL USE | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030097026-A1 | Process for the preparation of polyether polyols | PCBP1, FHIT, PUF60 | HSPA1A 3993/4885PTPN7 3152/4885SIRT1 4721/4885 |
| US-20010053866-A1 | Process for the preparation of polyether polyols | PCBP1, FHIT, PUF60 | HSPA1A 3993/4885PTPN7 3152/4885SIRT1 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.